Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
Type 1 diabetes can now be most accurately understood as a disease that progresses in three distinct stages.
TrialNet screening looks for five diabetes-related autoantibodies that signal an increased risk of T1D. The JDRF, ADA and Endocrine Society now classify having two or more of these autoantibodies as early stage T1D. Finding T1D in its earliest stage allows for prompt intervention aiming to change the course of the disease.
T1D starts with a genetic predisposition—gene(s) that put you at higher risk. Risk for people in the general population is about 1 in 300. If you have a family member with T1D, your risk is 1 in 20.
There are three distinct stages of T1D. The first two stages can be identified by TrialNet screening prior to symptoms. Our goal is to identify the disease in its earliest stage and stop disease progression by preserving beta cell production.